{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:22:29Z","timestamp":1792498949709,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007693","name":"King Chulalongkorn Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["498\/65"],"award-info":[{"award-number":["498\/65"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["546\/64"],"award-info":[{"award-number":["546\/64"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["TCTR 20210910002"],"award-info":[{"award-number":["TCTR 20210910002"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010724","name":"Health Systems Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011057","name":"National Center for Genetic Engineering and Biotechnology","doi-asserted-by":"publisher","award":["P2051613"],"award-info":[{"award-number":["P2051613"]}],"id":[{"id":"10.13039\/501100011057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.heliyon.2023.e23892","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T21:48:19Z","timestamp":1703022499000},"page":"e23892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4\/5 variants at 3\u20134 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3187-2621","authenticated-orcid":false,"given":"Suvichada","family":"Assawakosri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9482-6353","authenticated-orcid":false,"given":"Sitthichai","family":"Kanokudom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nungruthai","family":"Suntronwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jira","family":"Chansaenroj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chompoonut","family":"Auphimai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2250-0017","authenticated-orcid":false,"given":"Pornjarim","family":"Nilyanimit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeyaporn","family":"Vichaiwattana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanunrat","family":"Thongmee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaneeya","family":"Duangchinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warangkana","family":"Chantima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattarakul","family":"Pakchotanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donchida","family":"Srimuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thaksaporn","family":"Thatsanathorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirapa","family":"Klinfueng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natthinee","family":"Sudhinaraset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7953-275X","authenticated-orcid":false,"given":"Nasamon","family":"Wanlapakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juthathip","family":"Mongkolsapaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3852-9092","authenticated-orcid":false,"given":"Sittisak","family":"Honsawek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Poovorawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.heliyon.2023.e23892_bib1","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/jmv.27526","article-title":"Omicron and Delta variant of SARS\u2010CoV\u20102: a comparative computational study of spike protein","volume":"94","author":"Kumar","year":"2022","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e23892_bib3","article-title":"mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant","volume":"3","author":"Edara","year":"2022","journal-title":"Cell Rep Med"},{"issue":"6581","key":"10.1016\/j.heliyon.2023.e23892_bib4","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.abn7591","article-title":"Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine\u2013elicited human sera","volume":"375","author":"Muik","year":"2022","journal-title":"Science"},{"issue":"7898","key":"10.1016\/j.heliyon.2023.e23892_bib5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23892_bib6","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1093\/cid\/ciab1041","article-title":"Neutralization of severe acute respiratory syndrome coronavirus 2 omicron variant by sera from BNT162b2 or CoronaVac vaccine recipients","volume":"75","author":"Lu","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e23892_bib8","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/infdis\/jiac092","article-title":"Neutralizing activities against the omicron variant after a heterologous booster in healthy adults receiving two doses of CoronaVac vaccination","volume":"226","author":"Assawakosri","year":"2022","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23892_bib9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/vaccines10010086","article-title":"Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine","volume":"10","author":"Kanokudom","year":"2022","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e23892_bib10","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41591-022-01701-w","article-title":"Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil","volume":"28","author":"Cerqueira-Silva","year":"2022","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23892_bib11","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jinf.2022.04.018","article-title":"Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial","volume":"84","author":"Liu","year":"2022","journal-title":"J. Infect."},{"issue":"7902","key":"10.1016\/j.heliyon.2023.e23892_bib12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa","volume":"603","author":"Viana","year":"2022","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.heliyon.2023.e23892_bib13","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.cell.2022.04.035","article-title":"Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike","volume":"185","author":"Yamasoba","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2023.e23892_bib14","series-title":"Continued Emergence and Evolution of Omicron in South Africa: New BA. 4 and BA. 5 Lineages","author":"Tegally","year":"2022"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23892_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28138","article-title":"The outbreak of SARS\u2010CoV\u20102 Omicron lineages, immune escape, and vaccine effectivity","volume":"95","author":"Zhou","year":"2022","journal-title":"J. Med. Virol."},{"issue":"21","key":"10.1016\/j.heliyon.2023.e23892_bib16","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1016\/j.cell.2022.09.018","article-title":"Virological characteristics of the novel SARS-CoV-2 Omicron variants including BA.2.12.1, BA.4 and BA.5","volume":"185","author":"Kimura","year":"2022","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23892_bib17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/vaccines10010086","article-title":"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine","volume":"10","author":"Kanokudom","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.heliyon.2023.e23892_bib18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ijid.2022.07.038","article-title":"Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination","volume":"122","author":"Assawakosri","year":"2022","journal-title":"Int. J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23892_bib19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jinf.2022.04.018","article-title":"Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial","volume":"84","author":"Liu","year":"2022","journal-title":"J. Infect."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e23892_bib20","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/s41591-021-01527-y","article-title":"Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis","volume":"27","author":"Choi","year":"2021","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e23892_bib21","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e23892_bib22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/vaccines9030238","article-title":"Correlates of vaccine-induced protection against SARS-CoV-2","volume":"9","author":"Koch","year":"2021","journal-title":"Vaccines"},{"issue":"32","key":"10.1016\/j.heliyon.2023.e23892_bib23","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23892_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28164","article-title":"Vaccine\u2010induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster","volume":"95","author":"Favresse","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.heliyon.2023.e23892_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101680","article-title":"Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: a randomised, double-blinded, placebo-controlled, phase 2 trial","volume":"54","author":"Zhang","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e23892_bib26","doi-asserted-by":"crossref","first-page":"E404","DOI":"10.1016\/S2666-5247(22)00060-X","article-title":"Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2","volume":"3","author":"Chen","year":"2022","journal-title":"Lancet Microbe"},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23892_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-30681-1","article-title":"Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine","volume":"13","author":"Kurhade","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2023.e23892_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2022.105273","article-title":"Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection","volume":"156","author":"Cheng","year":"2022","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.heliyon.2023.e23892_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876306","article-title":"Rapid hypermutation B cell trajectory recruits previously primed B cells upon third SARS-cov-2 mRNA vaccination","volume":"13","author":"Paschold","year":"2022","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.heliyon.2023.e23892_bib30","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMc2210546","article-title":"Durability of booster mRNA vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 subvariants","volume":"387","author":"Qu","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23892_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-31839-7","article-title":"Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil","volume":"13","author":"Cerqueira-Silva","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e23892_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33169-0","article-title":"Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil","volume":"13","author":"Ranzani","year":"2022","journal-title":"Nat. Commun."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023111005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023111005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:38:17Z","timestamp":1790656697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023111005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405844023111005"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23892","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.11.24.22282735","asserted-by":"object"}]},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4\/5 variants at 3\u20134 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e23892"}}